Biotech Values

[DewDiligence]

MNTA’s $5M milestone for FDA approval of generic Lovenox is separate from the $163M of remaining potential milestones from the 2006 NVS-MNTA collaboration. The $163M pertains to Lovenox in the EU, specifically, and to Copaxone.